We compared obinutuzumab, a humanised type II anti-CD20 monoclonal antibody that induces potent B-cell depletion, with placebo for the treatment of LN in combination with standard therapies. Methods ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback